RxDoctor Payments Data

John Crawford, DO

Family Medicine · Philadelphia, PANPI 1346301538

Payments from drug & device makers

$11,144in general payments, 2019–2025

Across 623 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • Lilly USA, LLC$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Novo Nordisk$761
  • Pfizer$536
  • plus $3K from 32 others

What the payments were for

  • Speaking & faculty fees$140%
  • Food & beverage$11,113100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,144 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,340
Medicare patients
151
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide93$101,487
EliquisApixaban96$69,995
FarxigaDapagliflozin Propanediol49$53,627
JardianceEmpagliflozin50$36,451
OzempicSemaglutide31$33,809
JanuviaSitagliptin Phosphate33$33,211
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$31,706
LinzessLinaclotide50$26,085
EntrestoSacubitril/Valsartan23$23,211
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$21,197
XareltoRivaroxaban14$19,445
MyrbetriqMirabegron18$13,031
MovantikNaloxegol Oxalate28$11,840
TrintellixVortioxetine Hydrobromide11$11,422
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$1,720$101,48793 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,270$78,94393 claims
PfizerEliquis$536$69,99596 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$2,605$47,54687 claims
Boehringer IngelheimJardiance$279$36,45150 claims
Novo NordiskOzempic$761$33,80931 claims
AbbVieLinzess$1,159$26,08550 claims
NovartisEntresto$204$23,21123 claims
Johnson & JohnsonXarelto$130$19,44514 claims
Astellas Pharma US IncMyrbetriq$91$13,03118 claims
Redhill Biopharma Inc.Movantik$15$11,84028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →